Physiological effects of slow release potassium phosphate for absorptive hypercalciuria

A randomized double-blind trial

Neil A. Breslau, Howard J. Heller, Alfredo A. Reza-Albarrán, Charles Y C Pak

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: We examined the physiological effects and tolerance of UroPhos- K,|| a slow release neutral form of potassium phosphate (155 mg. phosphate and 8 mEq. potassium per tablet) in patients with absorptive hypercalciuria. Materials and Methods: A total of 31 patients with absorptive hypercalciuria were studied at baseline and after 3 months of treatment with 4 tablets twice daily of UroPhos-K or placebo (identical in appearance) in a prospective randomized, placebo controlled, double-blind trial during a 4-day inpatient study with a daily constant metabolic diet containing 400 mg. calcium, 100 mEq. sodium and 800 mg. phosphate. Results: Treatment with UroPhos-K did not cause significant gastrointestinal side effects, increase fasting serum potassium or phosphorus, or reduce hemoglobin or creatinine clearance. It reduced urinary calcium excretion from 277 ± 72 to 166 ± 43 mg. per day (p <0.001), associated with a reduction in serum 1,25-dihydroxyvitamin D concentration from 50 ± 11 to 42 ± 9 pg./ml. (p <0.001). Indexes of intestinal calcium absorption and markers of bone turnover also decreased modestly. None of these changes was seen in the placebo group. Conclusions: In patients with absorptive hypercalciuria UroPhos-K seems to correct hypercalciuria by a combination of reduced intestinal absorption, bone resorption and improved renal calcium reabsorption. The drug is well tolerated compared to placebo.

Original languageEnglish (US)
Pages (from-to)664-668
Number of pages5
JournalJournal of Urology
Volume160
Issue number3 I
DOIs
StatePublished - 1998

Fingerprint

Hypercalciuria
Placebos
Calcium
Intestinal Absorption
Tablets
Potassium
Phosphates
Bone Remodeling
Bone Resorption
Serum
Phosphorus
Inpatients
Fasting
Creatinine
Hemoglobins
Sodium
Diet
potassium phosphate
Therapeutics
Pharmaceutical Preparations

Keywords

  • Calcium
  • Delayed-action preparations
  • Phosphates
  • Randomized controlled trials
  • Urinary calculi

ASJC Scopus subject areas

  • Urology

Cite this

Physiological effects of slow release potassium phosphate for absorptive hypercalciuria : A randomized double-blind trial. / Breslau, Neil A.; Heller, Howard J.; Reza-Albarrán, Alfredo A.; Pak, Charles Y C.

In: Journal of Urology, Vol. 160, No. 3 I, 1998, p. 664-668.

Research output: Contribution to journalArticle

Breslau, Neil A. ; Heller, Howard J. ; Reza-Albarrán, Alfredo A. ; Pak, Charles Y C. / Physiological effects of slow release potassium phosphate for absorptive hypercalciuria : A randomized double-blind trial. In: Journal of Urology. 1998 ; Vol. 160, No. 3 I. pp. 664-668.
@article{86f284c095954b508c3477a99d31338f,
title = "Physiological effects of slow release potassium phosphate for absorptive hypercalciuria: A randomized double-blind trial",
abstract = "Purpose: We examined the physiological effects and tolerance of UroPhos- K,|| a slow release neutral form of potassium phosphate (155 mg. phosphate and 8 mEq. potassium per tablet) in patients with absorptive hypercalciuria. Materials and Methods: A total of 31 patients with absorptive hypercalciuria were studied at baseline and after 3 months of treatment with 4 tablets twice daily of UroPhos-K or placebo (identical in appearance) in a prospective randomized, placebo controlled, double-blind trial during a 4-day inpatient study with a daily constant metabolic diet containing 400 mg. calcium, 100 mEq. sodium and 800 mg. phosphate. Results: Treatment with UroPhos-K did not cause significant gastrointestinal side effects, increase fasting serum potassium or phosphorus, or reduce hemoglobin or creatinine clearance. It reduced urinary calcium excretion from 277 ± 72 to 166 ± 43 mg. per day (p <0.001), associated with a reduction in serum 1,25-dihydroxyvitamin D concentration from 50 ± 11 to 42 ± 9 pg./ml. (p <0.001). Indexes of intestinal calcium absorption and markers of bone turnover also decreased modestly. None of these changes was seen in the placebo group. Conclusions: In patients with absorptive hypercalciuria UroPhos-K seems to correct hypercalciuria by a combination of reduced intestinal absorption, bone resorption and improved renal calcium reabsorption. The drug is well tolerated compared to placebo.",
keywords = "Calcium, Delayed-action preparations, Phosphates, Randomized controlled trials, Urinary calculi",
author = "Breslau, {Neil A.} and Heller, {Howard J.} and Reza-Albarr{\'a}n, {Alfredo A.} and Pak, {Charles Y C}",
year = "1998",
doi = "10.1016/S0022-5347(01)62749-6",
language = "English (US)",
volume = "160",
pages = "664--668",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3 I",

}

TY - JOUR

T1 - Physiological effects of slow release potassium phosphate for absorptive hypercalciuria

T2 - A randomized double-blind trial

AU - Breslau, Neil A.

AU - Heller, Howard J.

AU - Reza-Albarrán, Alfredo A.

AU - Pak, Charles Y C

PY - 1998

Y1 - 1998

N2 - Purpose: We examined the physiological effects and tolerance of UroPhos- K,|| a slow release neutral form of potassium phosphate (155 mg. phosphate and 8 mEq. potassium per tablet) in patients with absorptive hypercalciuria. Materials and Methods: A total of 31 patients with absorptive hypercalciuria were studied at baseline and after 3 months of treatment with 4 tablets twice daily of UroPhos-K or placebo (identical in appearance) in a prospective randomized, placebo controlled, double-blind trial during a 4-day inpatient study with a daily constant metabolic diet containing 400 mg. calcium, 100 mEq. sodium and 800 mg. phosphate. Results: Treatment with UroPhos-K did not cause significant gastrointestinal side effects, increase fasting serum potassium or phosphorus, or reduce hemoglobin or creatinine clearance. It reduced urinary calcium excretion from 277 ± 72 to 166 ± 43 mg. per day (p <0.001), associated with a reduction in serum 1,25-dihydroxyvitamin D concentration from 50 ± 11 to 42 ± 9 pg./ml. (p <0.001). Indexes of intestinal calcium absorption and markers of bone turnover also decreased modestly. None of these changes was seen in the placebo group. Conclusions: In patients with absorptive hypercalciuria UroPhos-K seems to correct hypercalciuria by a combination of reduced intestinal absorption, bone resorption and improved renal calcium reabsorption. The drug is well tolerated compared to placebo.

AB - Purpose: We examined the physiological effects and tolerance of UroPhos- K,|| a slow release neutral form of potassium phosphate (155 mg. phosphate and 8 mEq. potassium per tablet) in patients with absorptive hypercalciuria. Materials and Methods: A total of 31 patients with absorptive hypercalciuria were studied at baseline and after 3 months of treatment with 4 tablets twice daily of UroPhos-K or placebo (identical in appearance) in a prospective randomized, placebo controlled, double-blind trial during a 4-day inpatient study with a daily constant metabolic diet containing 400 mg. calcium, 100 mEq. sodium and 800 mg. phosphate. Results: Treatment with UroPhos-K did not cause significant gastrointestinal side effects, increase fasting serum potassium or phosphorus, or reduce hemoglobin or creatinine clearance. It reduced urinary calcium excretion from 277 ± 72 to 166 ± 43 mg. per day (p <0.001), associated with a reduction in serum 1,25-dihydroxyvitamin D concentration from 50 ± 11 to 42 ± 9 pg./ml. (p <0.001). Indexes of intestinal calcium absorption and markers of bone turnover also decreased modestly. None of these changes was seen in the placebo group. Conclusions: In patients with absorptive hypercalciuria UroPhos-K seems to correct hypercalciuria by a combination of reduced intestinal absorption, bone resorption and improved renal calcium reabsorption. The drug is well tolerated compared to placebo.

KW - Calcium

KW - Delayed-action preparations

KW - Phosphates

KW - Randomized controlled trials

KW - Urinary calculi

UR - http://www.scopus.com/inward/record.url?scp=0032322405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032322405&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)62749-6

DO - 10.1016/S0022-5347(01)62749-6

M3 - Article

VL - 160

SP - 664

EP - 668

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3 I

ER -